Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Future directions of immune cell therapy in lymphoma

Yago Nieto • 15 Feb 2021
TCT 2021
Lymphoma

Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, explores the next stages of immunotherapy and cellular therapy for patients with lymphoma, including the use of novel immune cells as well as improving the efficacy of T-cell approaches to prevent T-cell exhaustion and enhance T-cell localization. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Yago Nieto

2:10
High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma
Yago Nieto • 11 Dec 2023
2:55
AFM13 with cord blood-derived NK-cell therapy in patients with refractory CD30-positive lymphomas
Yago Nieto • 11 Dec 2023
3:32
Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma
Yago Nieto • 13 Feb 2023
2:33
Phase I/II study of olaparib plus vorinostat/GemBuMel with autoSCT in R/R lymphomas
Yago Nieto • 11 Dec 2022

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals